The Patent Finder

Kairos Pharma, Ltd.

Also on record
Records under this name other than the patents Kairos Pharma, Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.

Showing 1 to 5 of 5 · Back to Kairos Pharma, Ltd.

PatentTitleStatus Expires Confidence
US 10,336,831Use of anti-endoglin antibodies for treating ocular fibrosis
Lapsed on the fee record
Ended Jul 2, 2023 · From the USPTO record
Lapsed on the fee recordEnded Jul 2, 2023From the USPTO record
US 10,155,820Anti-endoglin antibodies and uses thereof
Lapsed on the fee record
Ended Dec 18, 2022 · From the USPTO record
Lapsed on the fee recordEnded Dec 18, 2022From the USPTO record
US 9,926,375Anti-endoglin antibodies and uses thereof
Lapsed on the fee record
Ended Mar 27, 2022 · From the USPTO record
Lapsed on the fee recordEnded Mar 27, 2022From the USPTO record
US 8,609,094Endoglin antibodies
Lapsed on the fee record
Ended Dec 17, 2021 · From the USPTO record
Lapsed on the fee recordEnded Dec 17, 2021From the USPTO record
US 9,518,122Endoglin antibodies
Lapsed on the fee record
Ended Dec 13, 2020 · From the USPTO record
Lapsed on the fee recordEnded Dec 13, 2020From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited